Validation of tissue microarray technology in malignantpleural mesothelioma

Pathology

Volumn 43, Issue 2, 2011, Pages 128-132

  Kao, Steven C H ^a,b,c   Lee, Kenneth ^d   Armstrong, Nicola J ^e   Clarke, Stephen ^a,b,c   Vardy, Janette ^b,c   Zandwijk, Nico Van ^a,c   Reid, Glen ^a,c   Burn, Juliet ^f   McCaughan, Brian C ^a,g   Henderson, Douglas W ^b,h   Klebe, Sonja ^b,h  

^a Bernie Banton Centre   (Australia)

^b SYDNEY CANCER CENTRE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Department of Microbiology and Infectious Diseases   (Australia)

^e GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^f Davies Campbell de Lambert Pathology   (Australia)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^h FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Calretinin; D2 40; Malignant mesothelioma; Tissue microarray

Indexed keywords

CALBINDIN; CALRETININ; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY D2-40; TUMOR MARKER;

ARTICLE; HUMAN; MESOTHELIOMA; METABOLISM; METHODOLOGY; PLEURA TUMOR; REPRODUCIBILITY; TISSUE MICROARRAY; VALIDATION STUDY;

ANTIBODIES, MONOCLONAL; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS; REPRODUCIBILITY OF RESULTS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79955953946     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e328342016c     Document Type: Article

References (32)

1. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for highthroughput molecularprofiling of tumor specimens. Nat Med 1998; 14: 844-7. (Pubitemid 28331029)
2. Camp R, Neumeister V, Rimm D. A decade of tissuemicroarrays:prognosis in the discovery and validation of cancer biomarkers. J Clin Oncol 2008; 26: 5630-7.
3. Bubendorf L, Nocito A, Moch H, et al. Tissue microarray (TMA) technology: miniaturizedpathology archives for high-thoughput in situ studies. J Pathol 2001; 195: 72-9.
4. Hassan S, Ferrario C, Mamo A, et al. Tissue microarrays: emerging standard for biomarker validation. Curr Opin Biotechnol 2008; 19: 19-25. (Pubitemid 351226513)
5. Schramlp, Kononen J, Bubendorf L, et al. Tissue microarrays for gene amplication surveys in many different tumor types. Clin Cancer Res 1999; 5: 1966-75. (Pubitemid 29399245)
6. Rosen D, Huang X, Deavers M, et al. Validation of tissue microarray technology in ovarian carcinoma. Mod pathol 2004; 17: 790-7.
7. Nocito A, Bubendorf L, Tinner E, et al. Microarrays of bladder cancer tissue are highly representative ofproliferation index and histological grade. J Pathol 2001; 194: 349-57. (Pubitemid 32624562)
8. Gulmann C, Butler D, Kay E, et al. Biopsy of a biopsy: validation of immunoprofiling in gastric cancer biopsy tissue microarrays. Histopathology 2003; 42: 70-6. (Pubitemid 36062570)
9. Camp R, Charette L, Rimm D. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000; 80: 1943-9. (Pubitemid 32012762)
10. Jourdan F, Sebbagh N, Comperat E, et al. Tissue microarray technology: validation in colorectal carcinoma and analysis ofp53, hMLH1, and hMSH2 immunohistochemical expression. Virchows Arch 2003; 443: 115-21. (Pubitemid 37056134)
11. Engellau J, Akerman M, Anderson H, et al. Tissue microarray technique in soft tissue sarcoma: immunohistochemical Ki-67 expression in malignant fibrous histiocytoma. Appl ImmunohistochemMol Morphol 2001; 9: 358-63. (Pubitemid 33098147)
12. Hinterberger M, Reineke T, Storz M, et al. D2-40 and calretinin - a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation. Mod pathol 2007; 20: 248-55. (Pubitemid 46422180)
13. Bishop J, Sharma R, Illeip. Naspsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast,pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol 2010; 41: 20-5.
14. Padgett D, Cathro H, Wick M, et al.podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin. Am J Surgpathol 2008; 32: 123-7.
15. Schramm A, Opitz I, Thies S, et al.prognostic significance of epithelialmesenchymal transition in malignantpleural mesothelioma. Eur J Cardiothorac Surg 2010; 37: 566-72.
16. Opitz I, Soltermann A, Abaecherli M, et al.pTEN expression is a strongpredictor of survival in meostheliomapatients. Eur J Cardiothorac Surg 2008; 33: 502-6.
17. Kothmaier H, Quehenberger F, Halbwedl I, et al. EGFR andpDGFR differentiallypromote growth in malignant epithelioid mesothelioma of short and long term survivors. Thorax 2007; 63: 345-51. (Pubitemid 351497948)
18. Kettunen E, Nicholson A, Nagy B, et al. L1CAM, INP10,p-cadherin, tPA and ITGB4 over-expression in malignantpleural mesotheliomas revealed by combined use of cDNA and tissue microarray. Carcinogenesis 2005; 26: 17-25. (Pubitemid 40207695)
19. Gordon G, Rockwell G, Jensen RR, et al. Identificaiton of novel candidate oncogenes and tumor suppressors in malignantpleural mesothelioma using large-scale transcriptionalprofiling. Am J Pathol 2005; 166: 1827-40. (Pubitemid 40734405)
20. Gordon G, Mani M, Mukhopadhyay L, et al. Expressionpatterns of inhibitor of apoptosisproteins in malignantpleural mesothelioma. J Pathol 2007; 211: 447-54. (Pubitemid 46332556)
21. Bidlingmaier S, He J,Wang Y, et al. Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognsizes both epithelioid and sarcomatoid types of mesothelioma. Cancer Res 2009; 69: 1570-7.
22. Shukla A, Bosenberg M, MacPherson M, et al. Activated cAMP response element bindingprotein is overexpressed in human mesotheliomas and inhibits apoptosis. Am J Pathol 2009; 175: 2197-206.
23. Romagnoli S, Fasoli E, Vaira V, et al. Identification ofpotential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis. Am J Pathol 2009; 174: 762-70.
24. Henderson DW, Shilkin KB, Whitaker D, et al. Thepathology of malignant mesothelioma, including immunohistology and ultrastructure. In: Henderson DW, Shilkin KB, Langlois SLP, Whitaker D, editors. Malignant Mesothelioma. New York: Hemispherepublishing Corporation, 1992; 69-139.
25. Muller A, Franke F, Muller D. D2-40: a reliable marker in the diagnosis ofpleural mesothelioma.pathobiology 2006; 73: 50-4. (Pubitemid 43952605)
26. Chu A, Litzky L,pasha T, et al. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod pathol 2005; 18: 105-10. (Pubitemid 40128102)
27. Ordóñez NG. D2-40 andpodoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol 2005; 36: 372-80. (Pubitemid 40591807)
28. Travis WD, Brambilla E, Muller-Hermelink HK, et al. World Health Organisation classification of tumours.pathology and genetics of the lung,pleura, thymus and heart. Lyon: IARCpress; 2004.
29. Shroutp, Fleiss J. Intraclass correlations: uses in assessing rater reliability.psychol Bull 1979; 86: 420-8.
30. Attanoos RL, Gibbs AR. The comparative accuracy of differentpleural biopsy techniques in the diagnosis of malignant mesothelioma. Histopathology 2008; 53: 340-4.
31. Kao SCH, Yan T, Lee K, et al. Accuracy of diagnostic biopsy for the histological subtype of malignantpleural mesothelioma. J Thorac Oncol 2010; (inpress).
32. Pintilie M, Iakovlev V, Fyles A, et al. Heterogeneity andpower in clinical biomarker studies. J Clin Oncol 2009; 27: 1517-21.